Built and used inside SMEDTEC, a working regulatory consultancy.

SMEDTEC Intelligence | FDA's AI & Robotics Push, Six New De Novo Classifications, MHRA Safety Signals & More

This fortnight's regulatory landscape was dominated by an unusually high volume of FDA de novo classifications — many touching AI, software, and emerging device categories — alongside a significant FDA policy signal on telesurgery and autonomous robotics. On the UK side, MHRA published its 2026–2030 patient and public involvement strategy and issued a safety advisory on a Duchenne muscular dystrophy treatment linked to patient deaths. Canada updated its establishment-licence guidance, and the Philips DOJ settlement delivered a stark reminder of the financial and reputational risks of recall mismanagement. Read on for the eight items your regulatory team needs to track right now.

FDA Classifies AI-Powered Digital Cervical Cytology Imaging System as Class II

FDA · US

This de novo order establishes a formal Class II (special controls) pathway for AI-driven cervical cytology slide imaging — creating a regulatory template that manufacturers of comparable AI-assisted pathology tools can reference for 510(k) submissions. Teams developing AI/ML diagnostic software should study the special controls language carefully, as it will shape predicate-based submissions across hematology and pathology device categories.

Read the source →

FDA Classifies Prognostic Assessment Software for Mild Cognitive Impairment as Class II

FDA · US

A second high-profile AI software de novo order in the same week creates a Class II classification for cognitive-impairment prognostic software. Together with the cervical cytology decision, this signals FDA is actively building a special-controls framework for AI-driven Software as a Medical Device (SaMD) across multiple specialties. Developers of neuro-AI tools now have concrete special controls to design against.

Read the source →

FDA Classifies Four Additional Device Types as Class II in a Single Fortnight (Radiology AI, Skin Cancer Software, OTC Sleep Apnea Risk Assessor, Spinal Imaging System)

FDA · US

Four further de novo classifications — radiology AI for fibrotic lung disease, software-aided skin-cancer adjunctive diagnostics, an OTC sleep-apnea risk device, and a spinal imaging system for neuraxial procedures — were published in the same two-week window. This volume of simultaneous de novo orders is notable: each creates a new 510(k) predicate, reduces barriers for comparable devices, and sets the special-controls bar competitors and follow-on manufacturers must meet. Regulatory teams should review the special controls documents for any device types adjacent to their portfolios.

Read the source →

FDA Seeks Public Input on Telesurgery and Autonomous Robotics Policy

INDUSTRY · GLOBAL

FDA has published a discussion paper on robotic medical devices with autonomous or remote teleoperation functions and is inviting public comment. This is an early-stage but strategically important signal: manufacturers developing telesurgical systems, autonomous procedure robots, or remotely operated devices should engage now to shape the regulatory framework before formal guidance is issued. Comment submissions are a direct opportunity to influence special controls and performance testing expectations.

Read the source →

MHRA Issues Safety Advisory on Givinostat (Duvyzat) Following Deaths in DMD Patients

MHRA · UK

MHRA has issued interim risk-mitigation advice following international reports of deaths in Duchenne muscular dystrophy patients treated with givinostat. While this is a medicines alert rather than a device notice, it carries direct implications for combination-product manufacturers, clinical investigators running DMD trials, and any organisation whose devices are used alongside givinostat in DMD management. Post-market surveillance teams should check whether their vigilance data intersects with this patient population.

Read the source →

MHRA Publishes Patient and Public Involvement & Engagement Plan 2026–2030

MHRA · UK

MHRA's new five-year plan formalises how patient experience will inform regulatory decisions, safety monitoring, and innovation pathways. For device manufacturers, this means increasing expectations to demonstrate meaningful patient involvement in clinical evaluation, benefit-risk determinations, and post-market follow-up — mirroring EU MDR requirements for patient consultation. Regulatory affairs teams should begin aligning internal patient engagement processes with MHRA's stated priorities ahead of the plan's full embedding.

Read the source →

Philips Pays €288 Million DOJ Settlement Over Recalled CPAP Devices

INDUSTRY · GLOBAL

Philips' agreement to pay €288 million to settle the US Department of Justice investigation stemming from its mass CPAP/ventilator recall is one of the largest medtech enforcement outcomes in recent years. It underscores the financial, criminal, and reputational consequences of inadequate post-market surveillance, delayed field safety corrective actions, and risk-assessment failures. Regulatory and quality leaders at any organisation with active recalls or FSCAs should use this case to stress-test their own recall-readiness and complaint-handling systems.

Read the source →

Health Canada Updates Medical Device Establishment Licence Application Form and Guidance (FRM-0292 / GUI-0016)

Health Canada · CA

Health Canada has revised the establishment licence application form and its supporting guidance document — a procedural update that affects any manufacturer or importer holding or applying for a Canadian MDEL. Companies distributing into Canada should verify that their current applications and internal procedures reference the updated form version to avoid processing delays or compliance gaps.

Read the source →

Get this in your inbox

Built by SMEDTEC OS

The regulatory operating system for the medical device supply chain.

Start free trial →